For the first quarter of 2011, the company’s net income was EUR1.29bn, compared to EUR1.79bn in the prior year period.
The company has generated gross profit of EUR5.83bn, compared to EUR6.07bn for the same period in 2010.
Sanofi-aventis‘ operating income was EUR1.36bn, compared to EUR2.15bn for the same period in 2010.
Sanofi-aventis CEO Christopher Viehbacher said he is satisfied with the performance of their growth platforms which were up 15.5% (excluding A/H1N1) and now represent almost 60% of group sales; these businesses have compensated for the impact of generic competition on net sales and represent the future of our company.